Quick Answer
Quince Therapeutics, Inc. reported Stockholders Equity of $30.15 million for fiscal year 2024.
Quince Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $30.15M | -64.6% |
| 2023 | $85.08M | -15.4% |
| 2022 | $100.59M | -15.2% |
| 2021 | $118.59M | -31.2% |
| 2020 | $172.26M | +49.2% |
| 2019 | $115.48M | +453.9% |
| 2018 | -$32.63M | -60.9% |
| 2017 | -$20.28M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.06M | -97.6% | -91.0% |
| June 30, 2025 | $11.74M | -75.0% | -36.8% |
| March 31, 2025 | $18.58M | -75.0% | -38.4% |
| December 31, 2024 | $30.15M | -64.6% | -32.9% |
| September 30, 2024 | $44.93M | -46.0% | -4.3% |
| June 30, 2024 | $46.97M | -45.9% | -36.7% |
| March 31, 2024 | $74.18M | -17.8% | -12.8% |
| December 31, 2023 | $85.08M | -15.4% | +2.3% |
- Quince Therapeutics, Inc. showed a decrease of -64.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2024 period, Quince Therapeutics, Inc.’s stockholders equity has grown by 248.6% (from -$20.28 million to $30.15 million).
- The most recent figure is from Quince Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: